UniProtKB/Swiss-Prot Q02556 : Variant p.Lys108Glu
Interferon regulatory factor 8
Feedback ?
Variant information
Variant position:
108
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
Disclaimer : Variants classification is intended for research purposes only, not for clinical and diagnostic use . The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant. ]
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
108 (K108E, p.Lys108Glu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution).following page
Variant description:
Any additional useful information about the variant.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
108
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
426
The length of the canonical sequence.
Location on the sequence:
K VYRIVPEEEQKCKLGVATAG
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human KSPDFEEVTDRSQLDISEPYK VYRIVPEEEQKCKLGVATAG
Mouse KSPDFEEVTDRSQLDISEPYK VYRIVPEEEQKCKLGVAPAG
Chicken KSPDFEEVTDRSQLDISEPYK VYRIVPEEEQKCKIGVGNGS
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 426 Interferon regulatory factor 8
DNA binding
7 – 114 IRF tryptophan pentad repeat
Mutagenesis
108 – 108 K -> H. In resting macrophages, no effect on cytoplasmic subcellular localization. Decreased nuclear subcellular localization upon IFN-gamma induction. Partial loss of IRF1-dependent transcriptional activator activity.
Mutagenesis
108 – 108 K -> Q. In resting macrophages, no effect on cytoplasmic subcellular localization. Loss of nuclear subcellular localization upon IFN-gamma induction. Loss of IRF1-dependent transcriptional activator activity.
Mutagenesis
108 – 108 K -> R. In resting macrophages, no effect on cytoplasmic subcellular localization. No effect on nuclear subcellular localization upon IFN-gamma induction. No effect on transcriptional activator activity. No effect on IRF1-dependent transcriptional activator activity.
Literature citations
IRF8 mutations and human dendritic-cell immunodeficiency.
Hambleton S.; Salem S.; Bustamante J.; Bigley V.; Boisson-Dupuis S.; Azevedo J.; Fortin A.; Haniffa M.; Ceron-Gutierrez L.; Bacon C.M.; Menon G.; Trouillet C.; McDonald D.; Carey P.; Ginhoux F.; Alsina L.; Zumwalt T.J.; Kong X.F.; Kumararatne D.; Butler K.; Hubeau M.; Feinberg J.; Al-Muhsen S.; Cant A.; Abel L.; Chaussabel D.; Doffinger R.; Talesnik E.; Grumach A.; Duarte A.; Abarca K.; Moraes-Vasconcelos D.; Burk D.; Berghuis A.; Geissmann F.; Collin M.; Casanova J.L.; Gros P.;
N. Engl. J. Med. 365:127-138(2011)
Cited for: VARIANT IMD32A ALA-80; VARIANT IMD32B GLU-108; CHARACTERIZATION OF VARIANT IMD32A ALA-80; CHARACTERIZATION OF VARIANT IMD32B GLU-108; INVOLVEMENT IN IMD32A; INVOLVEMENT IN IMD32B;
Functional characterization of the human dendritic cell immunodeficiency associated with the IRF8(K108E) mutation.
Salem S.; Langlais D.; Lefebvre F.; Bourque G.; Bigley V.; Haniffa M.; Casanova J.L.; Burk D.; Berghuis A.; Butler K.M.; Leahy T.R.; Hambleton S.; Gros P.;
Blood 124:1894-1904(2014)
Cited for: CHARACTERIZATION OF VARIANT IMD32B GLU-108; FUNCTION; SUBCELLULAR LOCATION; UBIQUITINATION; DESUMOYLATION; MUTAGENESIS OF LYS-108;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.
